CSF Markers of Oxidative Stress Are Associated with Brain Atrophy and Iron Accumulation in a 2-Year Longitudinal Cohort of Early MS

In this prospective longitudinal study, we quantified regional brain volume and susceptibility changes during the first two years after the diagnosis of multiple sclerosis (MS) and identified their association with cerebrospinal fluid (CSF) markers at baseline. Seventy patients underwent MRI (T1 and susceptibility weighted images processed to quantitative susceptibility maps, QSM) with neurological examination at the diagnosis and after two years. In CSF obtained at baseline, the levels of oxidative stress, products of lipid peroxidation, and neurofilaments light chain (NfL) were determined. Brain volumetry and QSM were compared with a group of 58 healthy controls. In MS patients, regional atrophy was identified in the striatum, thalamus, and substantia nigra. Magnetic susceptibility increased in the striatum, globus pallidus, and dentate and decreased in the thalamus. Compared to controls, MS patients developed greater atrophy of the thalamus, and a greater increase in susceptibility in the caudate, putamen, globus pallidus and a decrease in the thalamus. Of the multiple calculated correlations, only the decrease in brain parenchymal fraction, total white matter, and thalamic volume in MS patients negatively correlated with increased NfL in CSF. Additionally, negative correlation was found between QSM value in the substantia nigra and peroxiredoxin-2, and QSM value in the dentate and lipid peroxidation levels.

[1]  V. Fleischer,et al.  Serum Neurofilament Identifies Patients With Multiple Sclerosis With Severe Focal Axonal Damage in a 6-Year Longitudinal Cohort , 2022, Neurology: Neuroimmunology & Neuroinflammation.

[2]  F. Barkhof,et al.  Neurofilament-light and contactin-1 association with long-term brain atrophy in natalizumab-treated relapsing-remitting multiple sclerosis , 2022, Multiple sclerosis.

[3]  J. Riolo,et al.  Thalamic atrophy measured by artificial intelligence in a multicentre clinical routine real-world study is associated with disability progression , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  C. D’Mello,et al.  Expression of antioxidant enzymes in lesions of multiple sclerosis and its models , 2022, Scientific Reports.

[5]  Jack A. Reeves,et al.  Susceptibility networks reveal independent patterns of brain iron abnormalities in multiple sclerosis , 2022, NeuroImage.

[6]  P. Dušek,et al.  Oxidative Stress Markers in Cerebrospinal Fluid of Newly Diagnosed Multiple Sclerosis Patients and Their Link to Iron Deposition and Atrophy , 2022, Diagnostics.

[7]  D. Arnold,et al.  Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials , 2022, Frontiers in Immunology.

[8]  P. Klivényi,et al.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations , 2022, International journal of molecular sciences.

[9]  K. Mucha,et al.  Peroxiredoxins as Markers of Oxidative Stress in IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis , 2021, Archivum Immunologiae et Therapiae Experimentalis.

[10]  P. Dušek,et al.  Age-related magnetic susceptibility changes in deep grey matter and cerebral cortex of normal young and middle-aged adults depicted by whole brain analysis. , 2021, Quantitative imaging in medicine and surgery.

[11]  Alaa Abdelghani,et al.  Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease characteristics. , 2021, Multiple sclerosis and related disorders.

[12]  O. Ciccarelli,et al.  Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis , 2021, Neurology.

[13]  M. Dwyer,et al.  Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI , 2020, Human brain mapping.

[14]  R. Benedict,et al.  Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross‐Sectional Structural MRI Study , 2020, Journal of magnetic resonance imaging : JMRI.

[15]  M. Ramanathan,et al.  Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis , 2020, Diagnostics.

[16]  Shaojie Shi,et al.  Oxidative Stress Marker Aberrations in Multiple Sclerosis: A Meta-Analysis Study , 2020, Frontiers in Neuroscience.

[17]  E. Stern,et al.  Regional microglial activation in the substantia nigra is linked with fatigue in MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[18]  J. Lötjönen,et al.  Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis , 2020, Frontiers in Neurology.

[19]  P. Dušek,et al.  Deep Gray Matter Iron Content in Neuromyelitis Optica and Multiple Sclerosis , 2020, BioMed research international.

[20]  L. Kappos,et al.  Monitoring of radiologic disease activity by serum neurofilaments in MS , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[21]  M. Mori,et al.  Peroxiredoxins are involved in the pathogenesis of multiple sclerosis and neuromyelitis optica spectrum disorder , 2020, Clinical and experimental immunology.

[22]  C. Enzinger,et al.  Serum neurofilament light levels in normal aging and their association with morphologic brain changes , 2020, Nature Communications.

[23]  E. Havrdová,et al.  Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis , 2020, Multiple sclerosis.

[24]  D. Hunt,et al.  Cerebrospinal fluid neurofilament light chain in multiple sclerosis and its subtypes: a meta-analysis of case–control studies , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[25]  Phillip G. D. Ward,et al.  Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in friedreich ataxia , 2019, Movement disorders : official journal of the Movement Disorder Society.

[26]  A. Traboulsee,et al.  Increased mean R2* in the deep gray matter of multiple sclerosis patients: Have we been measuring atrophy? , 2018, Journal of magnetic resonance imaging : JMRI.

[27]  X. Montalban,et al.  Multiple sclerosis: clinical aspects , 2018, Current opinion in neurology.

[28]  M. Maciejczyk,et al.  Redox Balance, Antioxidant Defense, and Oxidative Damage in the Hypothalamus and Cerebral Cortex of Rats with High Fat Diet-Induced Insulin Resistance , 2018, Oxidative medicine and cellular longevity.

[29]  Oliver Speck,et al.  A robust multi-scale approach to quantitative susceptibility mapping , 2018, NeuroImage.

[30]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[31]  J. Wolff,et al.  Synaptic pathology in the cerebellar dentate nucleus in chronic multiple sclerosis , 2017, Brain pathology.

[32]  C Langkammer,et al.  Thalamic Iron Differentiates Primary-Progressive and Relapsing-Remitting Multiple Sclerosis , 2017, American Journal of Neuroradiology.

[33]  Robert Zivadinov,et al.  Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain , 2017, NeuroImage: Clinical.

[34]  W. Brück,et al.  Expression of the Antioxidative Enzyme Peroxiredoxin 2 in Multiple Sclerosis Lesions in Relation to Inflammation , 2017, International journal of molecular sciences.

[35]  Dan Wu,et al.  MRICloud: Delivering High-Throughput MRI Neuroinformatics as Cloud-Based Software as a Service , 2016, Computing in Science & Engineering.

[36]  Yan Zhang,et al.  Longitudinal change in magnetic susceptibility of new enhanced multiple sclerosis (MS) lesions measured on serial quantitative susceptibility mapping (QSM) , 2016, Journal of magnetic resonance imaging : JMRI.

[37]  Christian Enzinger,et al.  Dynamics of brain iron levels in multiple sclerosis , 2015, Neurology.

[38]  R. Bowtell,et al.  Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: A 7 Tesla MRI study , 2015, Journal of magnetic resonance imaging : JMRI.

[39]  Simon Hametner,et al.  Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[40]  Antonio Ayala,et al.  Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal , 2014, Oxidative medicine and cellular longevity.

[41]  O. Ciccarelli,et al.  Brain atrophy and lesion load predict long term disability in multiple sclerosis , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[42]  Ferdinand Schweser,et al.  Quantitative susceptibility mapping (QSM) as a means to measure brain iron? A post mortem validation study , 2012, NeuroImage.

[43]  Massimo Filippi,et al.  Association between pathological and MRI findings in multiple sclerosis , 2012, The Lancet Neurology.

[44]  Bernhard Hemmer,et al.  An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple Sclerosis , 2012, NeuroImage.

[45]  G. Ferretti,et al.  Peroxidation of lipoproteins in multiple sclerosis , 2011, Journal of the Neurological Sciences.

[46]  Hellmut Merkle,et al.  Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla. , 2011, Brain : a journal of neurology.

[47]  A. Iolascon,et al.  Oxidative stress modulates heme synthesis and induces peroxiredoxin-2 as a novel cytoprotective response in β-thalassemic erythropoiesis , 2011, Haematologica.

[48]  H. Lassmann,et al.  Oxidative damage in multiple sclerosis lesions , 2011, Brain : a journal of neurology.

[49]  D. Horáková,et al.  Multiple Sclerosis and the Accumulation of Iron in the Basal Ganglia: Quantitative Assessment of Brain Iron Using MRI T2 Relaxometry , 2010, European Neurology.

[50]  M. Keleş,et al.  Effect of Corticosteroid Therapy on Serum and CSF Malondialdehyde and Antioxidant Proteins in Multiple Sclerosis , 2001, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.